Editorial: infliximab or adalimumab as first- or second-line anti-TNF-conflicting evidence-authors' reply.
Visuri I, Eriksson C, Olén O, Cao Y, Mårdberg E, Grip O, Gustavsson A, Hjortswang H, Karling P, Montgomery S, Myrelid P, Ludvigsson JF, Halfvarson J.
Visuri I, et al. Among authors: ludvigsson jf.
Aliment Pharmacol Ther. 2021 Sep;54(6):848-849. doi: 10.1111/apt.16569.
Aliment Pharmacol Ther. 2021.
PMID: 34425010
No abstract available.